HK Stock Market Move | LEADS BIOLABS-B(09887) rose over 10% in morning trading, with two research abstracts selected for presentation at the 2026 AACR Annual Meeting.

LEADS BIOLABS-B(09887) rose over 10% in early trading, reaching an increase of 8.99% at the time of the report, at HK$80.65, with a trading volume of HK$321.88 million. On the news front, Vitality Bio announced that two preclinical pipeline research results will be presented at the 2026 American Association for Cancer Research (AACR) meeting. The two studies demonstrate the company's innovative research on cell engager-drug conjugates (TDC) and dual-target ADCs, further validating the company's three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform). It is worth noting that the company previously announced its annual performance, with total revenue of approximately HK$1.77 billion, derived mainly from the upfront and milestone payments of HK$177.3 million received under the licensing agreement with Dianthus Therapeutics for LBL-047. Research and development expenses were around HK$2.89 billion, representing a 55.7% year-on-year increase, mainly attributed to increased CMC development milestone expenditures related to the BLA submission preparation for LBL-024, accelerated patient enrollment and clinical progress for LBL-024 and LBL-034, and increased preclinical expenses as the company advances multiple pipeline assets to the IND preparation stage.